BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26092596)

  • 1. Expression of cancer stem cell markers in metastatic colorectal cancer correlates with liver metastasis, but not with metastasis to the central nervous system.
    Michl M; Heinemann V; Jung A; Engel J; Kirchner T; Neumann J
    Pathol Res Pract; 2015 Aug; 211(8):601-9. PubMed ID: 26092596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Stem Cell Markers Are Associated With Distant Hematogenous Liver Metastases But Not With Peritoneal Carcinomatosis in Colorectal Cancer.
    Neumann J; Löhrs L; Albertsmeier M; Reu S; Guba M; Werner J; Kirchner T; Angele M
    Cancer Invest; 2015; 33(8):354-60. PubMed ID: 26068177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic biomarkers for metastatic colorectal cancer].
    Neumann JH
    Pathologe; 2016 Nov; 37(Suppl 2):180-185. PubMed ID: 27638531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
    Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
    Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer.
    Michl M; Taverna F; Kumbrink J; Schiergens TS; Heinemann V; Engel J; Kirchner T; Neumann J
    Virchows Arch; 2021 Apr; 478(4):695-705. PubMed ID: 33300106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients.
    Pitule P; Cedikova M; Daum O; Vojtisek J; Vycital O; Hosek P; Treska V; Hes O; Kralickova M; Liska V
    Biomed Res Int; 2014; 2014():432139. PubMed ID: 24864242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
    Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
    Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metastasis suppressor, NDRG1, inhibits "stemness" of colorectal cancer via down-regulation of nuclear β-catenin and CD44.
    Wangpu X; Yang X; Zhao J; Lu J; Guan S; Lu J; Kovacevic Z; Liu W; Mi L; Jin R; Sun J; Yue F; Ma J; Lu A; Richardson DR; Wang L; Zheng M
    Oncotarget; 2015 Oct; 6(32):33893-911. PubMed ID: 26418878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR Signaling Combined with Cancer Stem Cell Markers as a Survival Predictor in Stage II Colorectal Cancer.
    Chang JY; Kim JH; Kang J; Park Y; Park SJ; Cheon JH; Kim WH; Kim H; Park JJ; Kim TI
    Yonsei Med J; 2020 Jul; 61(7):572-578. PubMed ID: 32608200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and phenotypic characterization of colorectal cancer stem cells with organ-specific metastatic potential.
    Gao W; Chen L; Ma Z; Du Z; Zhao Z; Hu Z; Li Q
    Gastroenterology; 2013 Sep; 145(3):636-46.e5. PubMed ID: 23747337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of metastatic site on the expression of CEA and cellular localization of β-catenin in colorectal cancer.
    Rao US; Hoerster NS; Thirumala S; Rao PS
    J Gastroenterol Hepatol; 2013 Mar; 28(3):505-12. PubMed ID: 23216017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD133+CD54+CD44+ circulating tumor cells as a biomarker of treatment selection and liver metastasis in patients with colorectal cancer.
    Fang C; Fan C; Wang C; Huang Q; Meng W; Yu Y; Yang L; Peng Z; Hu J; Li Y; Mo X; Zhou Z
    Oncotarget; 2016 Nov; 7(47):77389-77403. PubMed ID: 27764803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FUBP1 promotes colorectal cancer stemness and metastasis via DVL1-mediated activation of Wnt/β-catenin signaling.
    Yin H; Gao T; Xie J; Huang Z; Zhang X; Yang F; Qi W; Yang Z; Zhou T; Gao G; Yang X
    Mol Oncol; 2021 Dec; 15(12):3490-3512. PubMed ID: 34288405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter.
    Salnikov AV; Kusumawidjaja G; Rausch V; Bruns H; Gross W; Khamidjanov A; Ryschich E; Gebhard MM; Moldenhauer G; Büchler MW; Schemmer P; Herr I
    Cancer Lett; 2009 Mar; 275(2):185-93. PubMed ID: 19026485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic marker profiles for risk of distant metastases in colorectal cancer].
    Neumann J; Reu S; Kirchner T
    Pathologe; 2012 Feb; 33(1):39-44. PubMed ID: 22293788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis.
    Itatani Y; Kawada K; Fujishita T; Kakizaki F; Hirai H; Matsumoto T; Iwamoto M; Inamoto S; Hatano E; Hasegawa S; Maekawa T; Uemoto S; Sakai Y; Taketo MM
    Gastroenterology; 2013 Nov; 145(5):1064-1075.e11. PubMed ID: 23891973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Lgr5, a marker of intestinal stem cells, in colorectal cancer and its clinicopathological significance.
    He S; Zhou H; Zhu X; Hu S; Fei M; Wan D; Gu W; Yang X; Shi D; Zhou J; Zhou J; Zhu Z; Wang L; Li D; Zhang Y
    Biomed Pharmacother; 2014 Jun; 68(5):507-13. PubMed ID: 24751002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD44 is of functional importance for colorectal cancer stem cells.
    Du L; Wang H; He L; Zhang J; Ni B; Wang X; Jin H; Cahuzac N; Mehrpour M; Lu Y; Chen Q
    Clin Cancer Res; 2008 Nov; 14(21):6751-60. PubMed ID: 18980968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex.
    Choi HN; Kim KR; Lee JH; Park HS; Jang KY; Chung MJ; Hwang SE; Yu HC; Moon WS
    Oncol Rep; 2009 Jan; 21(1):57-63. PubMed ID: 19082443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer.
    Ribeiro KB; da Silva Zanetti J; Ribeiro-Silva A; Rapatoni L; de Oliveira HF; da Cunha Tirapelli DP; Garcia SB; Feres O; da Rocha JJ; Peria FM
    Cancer Biomark; 2016 Mar; 16(4):513-21. PubMed ID: 27062566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.